Amgen Inc. (NASDAQ:AMGN) Stock Holdings Decreased by Hall Laurie J Trustee

Hall Laurie J Trustee cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,195 shares of the medical research company’s stock after selling 385 shares during the period. Hall Laurie J Trustee’s holdings in Amgen were worth $1,936,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Provence Wealth Management Group lifted its stake in Amgen by 11.9% in the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after acquiring an additional 154 shares during the last quarter. Kinsale Capital Group Inc. lifted its stake in Amgen by 33.0% in the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after acquiring an additional 2,814 shares during the last quarter. Global Wealth Management Investment Advisory Inc. lifted its stake in Amgen by 2.4% in the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after acquiring an additional 109 shares during the last quarter. Valley Brook Capital Group Inc. lifted its stake in Amgen by 7.0% in the fourth quarter. Valley Brook Capital Group Inc. now owns 4,730 shares of the medical research company’s stock valued at $1,362,000 after acquiring an additional 310 shares during the last quarter. Finally, Evergreen Wealth Management LLC lifted its stake in Amgen by 1.7% in the fourth quarter. Evergreen Wealth Management LLC now owns 4,892 shares of the medical research company’s stock valued at $1,409,000 after acquiring an additional 84 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

NASDAQ:AMGN traded up $0.58 during mid-day trading on Tuesday, reaching $328.55. 1,352,484 shares of the company were exchanged, compared to its average volume of 2,599,579. Amgen Inc. has a 12 month low of $248.38 and a 12 month high of $346.85. The company has a fifty day moving average of $321.01 and a 200 day moving average of $299.19. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The stock has a market cap of $176.25 billion, a PE ratio of 46.94, a PEG ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same quarter in the previous year, the company posted $5.00 earnings per share. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, research analysts anticipate that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s dividend payout ratio is 128.57%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AMGN shares. TD Cowen boosted their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Mizuho boosted their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. BMO Capital Markets boosted their price objective on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Morgan Stanley reduced their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Finally, Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $326.89.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.